- Home
- NAAS vs HIND Comparison
NAAS vs HIND Comparison
Compare NAAS & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAAS | HIND |
|---|---|---|
| Founded | 2019 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 28.0M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NAAS | HIND |
|---|---|---|
| Price | $2.04 | $3.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 215.9K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.75 |
| 52 Week High | $4.54 | $12.87 |
Technical Indicators
Market Signals| Indicator | NAAS | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 52.52 |
| Support Level | $0.55 | $1.75 |
| Resistance Level | $3.77 | $3.89 |
| Average True Range (ATR) | 0.12 | 0.27 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 30.00 | 64.46 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.